Hao Shen

Company: Biosyngen Group

Job title: President

Seminars:

Panel Discussion: Ensuring Lasting Therapeutic Responses from Allogeneic Therapy – Is Redosing the Way to Go? 8:30 am

Examine the role of redosing in sustaining therapeutic efficacy and preventing disease relapse in patients receiving allogeneic therapies How do we determine if multiple doses are needed and if so, how do we determine how many? Is it better to use a one and done model or plan for multiple doses? Analyze the impact of treatment…Read more

day: Conference Day Two